Dose Blocked-randomized, Double-blind, Placebo Controlled, Single Dose, Dose-escalation Study to Investigate the Safety, Tolerability, Pharmacokinetic Characteristics of hzVSF-v13 After Intravenous Administration in Healthy Male Volunteers
Phase of Trial: Phase I
Latest Information Update: 06 Dec 2018
Price : $35 *
At a glance
- Drugs HzVSF-v13 (Primary)
- Indications Hepatitis B; Hepatitis C; Herpesvirus infections; Influenza virus infections; Viral infections
- Focus Pharmacokinetics
- Sponsors ImmuneMed
- 30 Nov 2018 Planned End Date changed from 1 Aug 2019 to 1 Oct 2019.
- 30 Nov 2018 Planned primary completion date changed from 1 May 2019 to 1 Aug 2019.
- 30 Nov 2018 Status changed from not yet recruiting to recruiting.